Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies

Stuart C. Gordon(Henry Ford Health System), Marlyn J. Mayo(The University of Texas Southwestern Medical Center), Won Young Tak(Kyungpook National University Hospital), John R. Lake(Gilead Sciences (United States)), John M. Vierling, Aliya Gulamhusein, Liana Gheorghe(Institutul Clinic Fundeni), Aparna Goel(Stanford University), Christopher L. Bowlus(University of Padua), Charles A. McWherter(CymaBay Therapeutics (United States)), Alexandra Steinberg(CymaBay Therapeutics (United States)), B. Freilich(Kansas City Research Institute), Cynthia Levy(University of Miami), Sook‐Hyang Jeong, Palak Trivedi, Joseph A. Odin(Icahn School of Medicine at Mount Sinai), Carmen Stanca, Stephen A. Harrison(Louisiana State University), Seung Up Kim(Pusan National University), Yun‐Jung Choi(CymaBay Therapeutics (United States)), Jonathan Huang, Brian B. Borg(National Institute of Diabetes and Digestive and Kidney Diseases), Lisa Forman(Center for Clinical Research (United States)), Guy Neff, Bruce R. Bacon(Saint Louis University), Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Galambos Michael, M Suárez González, Kehu Yang(China Medical University), Hillel Tobias, Douglas Thorburn(Royal Free London NHS Foundation Trust)

Unknown

January 1, 2021

Cited by 0

|Hepatology|2023|2.9k

|Journal of Hepatology|2023|2.7k

|New England Journal of Medicine|2013|1.8k

|The Lancet|2019|1.2k

|New England Journal of Medicine|2014|1.1k

Related Papers